Market access strategies, formularies, health technology assessment
Mexico’s Cofepris has granted marketing authorization for lenacapavir as twice-yearly injectable pre-exposure prophylaxis against HIV, placing Mexico among a small group of countries with regulatory access to the long-acting prevention …
The first new-class painkiller in decades has near-universal US coverage and negligible sales — and no clear path to Latin American patients.
Same bet, opposite outcomes: Rede D’Or’s insurer-hospital machine compounds while Hapvida’s verticalization buckles under claims, losses and member cuts.
Donanemab is now infused in a Mexican public hospital. Lilly’s 2026 target: 30 patients — the gap between innovation and the system, in one number.
Ecuador’s government is in talks with Colombia, India, Argentina, and Costa Rica to procure medicines for public hospitals, as shortages and a trade dispute with Colombia strain the health system.
Colombia’s highest administrative court suspended Decree 0182 on May 4, 2026, freezing a territorial restructuring of health insurers that would have forcibly reassigned an estimated 6.6 million affiliates.
Colombia’s Ministry of Health declared public interest grounds to pursue mandatory licensing of Gilead’s sofosbuvir-based hepatitis C patents, transferring the process to the competition authority for a final determination.
Uruguay’s Ministry of Public Health and mutual insurers have agreed to incorporate 12 high-cost medicines into the national formulary, reducing per-unit acquisition costs from up to 100,000 pesos to approximately …
Mexico’s Cofepris has established an abbreviated registration pathway recognising ANVISA evaluations, with a 45-business-day resolution ceiling — accelerating market entry for manufacturers already cleared in Brazil.
Ecuador’s Sercop signed 114 medication supply agreements in May–June 2026, but 71 carry no purchase orders as of mid-August — leaving contracted suppliers unpaid and public hospital shelves empty.
You must be logged in to post a comment.